Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib

Cancer Research

Volumn 70, Issue 11, 2010, Pages 4318-4326

  Chen, Siquan ^a,b   Blank, Jonathan L ^a   Peters, Theodore ^a,c   Liu, Xiaozhen J ^a   Rappoli, David M ^a,d   Pickard, Michael D ^a   Menon, Saurabh ^a   Yu, Jie ^a   Driscoll, Denise L ^a   Lingaraj, Trupti ^a   Burkhardt, Anne L ^a   Chen, Wei ^a   Garcia, Khristofer ^a   Sappal, Darshan S ^a   Gray, Jesse ^a   Hales, Paul ^a   Leroy, Patrick J ^a   Ringeling, John ^a   Rabino, Claudia ^a   Spelman, James J ^a   Morgenstern, Jay P ^a,d   Lightcap, Eric S ^a   more..

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c Department of Structural Biology   (United States)

^d Monsanto Biotechnology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; EPOXOMICIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; ML 912; MLN 2238; MLN 4924; MYC PROTEIN; PROTEASOME INHIBITOR; PROTEIN NOXA; PROTEIN P53; PUTRESCINE; SALINOSPORAMIDE A; SMALL INTERFERING RNA; SPERMIDINE; THAPSIGARGIN; UNCLASSIFIED DRUG;

ARTICLE; ASF1B GENE; BNIP3 GENE; CELL DEATH; CELL LINE; DNA DAMAGE; GENE; GENE IDENTIFICATION; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN GENOME; ODC1 GENE; PRIORITY JOURNAL; RIBOSOME; SMC1A GENE; SREBF1 GENE;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL DEATH; COLONIC NEOPLASMS; DNA DAMAGE; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HELA CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MELANOMA; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-MYC; PYRAZINES; RIBOSOMES; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 77953163141     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4428     Document Type: Article

References (35)

1. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008;14:1649-1657
2. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008;11:164-179
3. Nencioni A, Grünebach F, Patrone F, Ballestrero A, Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007; 21:30-36
4. Fribley A, Wang CY. Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress. Cancer Biol Ther 2006;5: 745-748
5. Iorns E, Lord CJ, Turner N, Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 2007;6:556-568
6. Whitehurst AW, Bodemann BO, Cardenas J, et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007;446:815-819
7. Fotheringham S, Epping MT, Stimson L, et al. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 2009;15:57-66.
8. Tsui M, Xie T, Orth JD, et al. An intermittent live cell imaging screen for siRNA enhancers and suppressors of a kinesin-5 inhibitor. PLoS One 2009;4:e7339.
9. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004;22:2108-2121
10. Crawford LJ, Walker B, Ovaa H, et al. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res 2006;66:6379-6386
11. Nawrocki ST, Carew JS, Dunner K, Jr., et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 2005;65: 11510-11519
12. Ding WX, Ni HM, Yin XM. Absence of Bax switched MG132-induced apoptosis to non-apoptotic cell death that could be suppressed by transcriptional or translational inhibition. Apoptosis 2007;12: 2233-2244
13. Uechi T, Tanaka T, Kenmochi N. A complete map of the human ribosomal protein genes: assignment of 80 genes to the cytogenetic map and implications for human disorders. Genomics 2001;72: 223-230 (Pubitemid 32281523)
14. Hanna J, Leggett DS, Finley D. Ubiquitin depletion as a key mediator of toxicity by translational inhibitors. Mol Cell Biol 2003;23:9251-9261
15. Dilling MB, Germain GS, Dudkin L, et al. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem 2002;277:13907-13917
16. Wu WK, Volta V, Cho CH, et al. Repression of protein translation and mTOR signaling by proteasome inhibitor in colon cancer cells. Biochem Biophys Res Commun 2009;386:598-601.
17. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008;8: 851-864
18. Schewe DM, Aguirre-Ghiso JA. Inhibition of eIF2α dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Cancer Res 2009;69:1545-1552
19. Obeng EA, Carlson LM, Gutman DM, et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907-4916
20. Decaux O, Clement M, Magrangeas F, et al. Inhibition of mTORC1 activity by REDD1 induction in myeloma cells resistant to bortezomib cytotoxicity. Cancer Sci 2009;101:889-897
21. Nikiforov MA, Riblett M, Tang WH, et al. Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci U S A 2007;104:19488-19493
22. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005;6:635-645
23. Schmidt EV. The role of c-myc in regulation of translation initiation. Oncogene 2004;23:3217-3221
24. Hyvönen MT, Keinänen TA, Cerrada-Gimenez M, et al. Role of hypusinated eukaryotic translation initiation factor 5A in polyamine depletion-induced cytostasis. J Biol Chem 2007;282:34700-34706
25. Jin BF, He K, Wang HX, et al. Proteomic analysis of ubiquitin-proteasome effects: insight into the function of eukaryotic initiation factor 5A. Oncogene 2003;22:4819-4830
26. Tome ME, Fiser SM, Payne CM, Gerner EW. Excess putrescine accumulation inhibits the formation of modified eukaryotic initiation factor 5A (eIF-5A) and induces apoptosis. Biochem J 1997;328: 847-854
27. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol 2006;16:253-64.
28. Ruggero D, Montanaro L, Ma L, et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004;10:484-486
29. Jacquemont C, Taniguchi T. Proteasome function is required for DNA damage response and Fanconi anemia pathway activation. Cancer Res 2007;67:7395-7405
30. Murakawa Y, Sonoda E, Barber LJ, et al. Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells. Cancer Res 2007;67:8536-8543
31. Shi W, Ma Z, Willers H, et al. Disassembly of MDC1 foci is controlled by ubiquitin-proteasome-dependent degradation. J Biol Chem 2008; 283:31608-31616
32. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917
33. Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood 2005;106:698-705.
34. Wang ZM, Chen ZP, Xu ZY, et al. In vitro evidence for homologous recombinational repair in resistance to melphalan. J Natl Cancer Inst 2001;93:1473-1478
35. Yarde DN, Oliveira V, Mathews L, et al. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res 2009;69:9367-9375